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Abstract
An evolution in healthcare is taking place throughout our country. Healthcare providers
are required to achieve an ever-growing number of regulatory and metric-driven standards. This
transformation aims to improve both the quality and cost of healthcare in the United States.
Diabetes mellitus (DM) is one of the most costly chronic diseases in the United States. Since DM
has high mortality, high morbidity, and low quality of life rates, it is no wonder that DM is one of
the focuses of the National Committee for Quality Assurance performance improvement tools
known as the Healthcare Effectiveness Data and Information Set (HEDIS). In addition, the
HEDIS set of metrics is increasingly being used to judge the quality of healthcare providers and
health systems, as well as link this performance to reimbursement. For healthcare providers to
remain financially viable, they need to score well on these metrics. The aim of this study was to
identify which common quantitative laboratory data elements in the Cerner Health Facts
database correlate to poorly controlled glycosylated hemoglobin (HbA1c) levels in adult patients
with DM that could be used in the future to create a mathematical model to predict which
patients may have poorly controlled HbA1c levels.
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CHAPTER 1: INTRODUCTION AND BACKGROUND
An evolution in healthcare is taking place throughout our country. Healthcare providers
are required to achieve an ever-growing number of regulatory and metric-driven standards. This
transformation aims to improve both the quality and cost of healthcare in the United States.
Healthcare spending in the United States accounted for 18% of the gross domestic product from
2009 through 2019, which is approximately twice as much as other high-income countries,
despite similar utilization rates (Centers for Medicare and Medicaid Services, 2020; Papanicolas
et al., 2018). Americans might be willing to pay more for a higher quality of care, but, despite the
high cost, our overall quality ranks last when compared to industrialized countries (Paterson,
2013; The Commonwealth Fund, 2020).
People with chronic health conditions account for 90% of national annual healthcare
expenditures. Of the chronic diseases, diabetes mellitus (DM) is one of the most costly, at $237
billion every year. With such a high cost, DM is more expensive than cancer, obesity,
Alzheimer’s, heart disease, or stroke (Centers for Disease Control and Prevention, 2019).
Additionally, DM has high mortality, high morbidity, and low quality of life rates (Trikkalinou et
al., 2017; Wilkinson et al., 2014). It is no wonder that DM is one of the focuses of the National
Committee for Quality Assurance (NCQA) performance improvement tools known as the
Healthcare Effectiveness Data and Information Set (HEDIS; Centers for Disease Control and
Prevention, 2017).
HEDIS is used by many organizations, including the Centers for Medicare and Medicaid
Services, to benchmark quality of care in more than 90 measures across 6 domains (NCQA,
2019). It has become commonplace for healthcare providers and health systems to be judged on
these measures, and reimbursement for services is increasingly linked to performance in these
areas. For healthcare providers to remain financially viable, they need to score well on these
metrics.
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As shown in Table 1, NCQA reported for the 2018 HEDIS (which includes both type 1
and type 2 DM patients) that the percentage of patients who had a glycosylated hemoglobin
(HbA1c) result that was considered controlled at less than 8% ranged from a low of 49%
(Medicaid health maintenance organization [HMO] patients) to a high of 68% (Medicare
preferred provider organization [PPO] patients). In addition, the percentage of patients who had
an HbA1c that was considered poorly controlled at greater than 9% ranged from a low of 20%
(Medicare PPO patients) to a high of 41% (Medicaid HMO patients) (NCQA, 2020). Therefore,
approximately one in three patients with DM in the report had poorly controlled HbA1c.
Table 1
2018 HEDIS HbA1c Results
Level of Control

Medicaid HMO (%)

Medicare PPO (%)

Controlled (HbA1c < 8%)

48.7

68.4

Poorly Controlled (HbA1c > 9%)

41.2

19.9

Problem Statement
Due to the perceived difficulty in controlling this disease and the high costs involved
both monetarily and healthwise, it is important to be able to identify the variables available in
electronic medical record (EMR) administrative data, which enables clinicians to predict and
eventually improve the HbA1c control of adult DM patients. The definition of administrative
data for the purposes of this research was any data that are generated and collected from any
encounter in a healthcare system (Cadarette & Wong, 2015).
Study Purpose and PICOT Question
The aim for this project was to identify which common quantitative laboratory data
elements in the Cerner Health Facts database (HFDB) correlate to poorly controlled HbA1c
levels of greater than 8% in adult patients with DM that could be used in the future to create a
mathematical model to predict which patients may have a poorly controlled HbA1c. The

14

question posed was: Which common quantitative laboratory variables in the HFDB correlate
with poorly controlled HbA1c (defined as HbA1c greater than or equal to 8%) in adult diabetic
patients’ data between July 1, 2016 and July 1, 2017? For the purposes of this study, common
laboratory variables are the components of a complete blood count, a comprehensive metabolic
panel, and a lipid profile.
Objectives and Goals
The goal of this quantitative study was to identify quantitative laboratory variables that
correlate with uncontrolled HbA1c in adult diabetic patients found in the HFDB. An objective of
the study was to add to the body of literature related to laboratory values correlated with
uncontrolled HbA1c. A literature review revealed that little research has been conducted on the
quantitative laboratory values found in many EMRs and their correlation to uncontrolled
HbA1c.
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CHAPTER 2: REVIEW OF THE LITERATURE
A literature review was conducted to determine what current research exists on HbA1c
values and the variables that influence it. The initial review focused on literature about the
relationship of blood glucose to other variables. Since literature directly related to this topic is
limited, additional studies were included that reviewed the predictive ability of EMR data.
Search Strategy
The first step in this research was describing the administrative data variables that are
identified in the literature. The literature search was conducted on the PubMed and the
Cumulative Index of Nursing and Allied Health Literature databases. This search focused on the
question: What administrative data variables influence HbA1c control in adult diabetic patients?
Search filters included English language only and human studies limited to adults 19 years of
age and older. Key words included A1C and administrative data. Due to the low number of
articles returned, the search time period was set to the past 10 years. This search resulted in a
total of 70 articles. After title review, four articles were identified for this paper, as they
appeared to most closely address the research question.
Due to the low number of applicable studies, an additional key word search was
performed with the same filters for the past 5 years changing the search words to EMR data and
predict to determine if EMR data has been used to predict outcomes. This search resulted in a
total of 130 articles. After removal of duplicates from the previous search and title review, an
additional four articles were identified for this paper, as they appeared to include data related to
using EMR data to predict future outcomes.
Literature Review
A wide range of variables were found in the reviewed literature. Main themes among the
variables were demographics, provider characteristics, socioeconomic factors, comorbidities,
duration of disease, medication, intensification, HbA1c/glucose levels, healthcare utilization,
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and EMR systems/data. Considering the diversity of variables found, it is helpful to consider the
findings for each type of variable in turn.
Demographics
Demographics are common data points found in administrative data and frequently used
in the investigation of health outcomes correlations. Demographic data points customarily
found in health system EMRs are age, gender, race, ethnicity, and geographic area. Less
frequently found are educational attainment and income level. In this literature review, age was
the most frequently assessed demographic in relation to HbA1c control (five studies). Three out
of the eight studies reviewed (Juarez et al., 2014; Kamal et al., 2014; LeBlanc et al., 2015) found
that those with controlled HbA1c tended to be older. Even though patient ages varied slightly
among the studies, the findings were relatively similar, as shown in Table 2.
Table 2
Level of HbA1c Control by Mean Age
Level of Control

Juarez et al., 2014

Kamal et al., 2014

Optimal

63.1

66.5

Poor

59.8

58.4

In addition, LeBlanc et al. (2015) found that each additional year of age increased the
odds of HbA1c being in optimal glycemic control by 2%. In contrast, Lee et al. (2018) reported
that of the patients with poorly controlled HbA1c, 57% were aged 45 to 64, and only 27% were
aged greater than or equal to 65. Related to this, Li et al. (2019) found that patients aged 85 or
older were negatively associated with hypoglycemia (odds ratio [OR] 0.6). Considering that age
is not a laboratory value, its relationship to HbA1c values was not reviewed in this study.
Another commonly found demographic in EMRs is gender. Three of the eight studies
reviewed gender in relationship to HbA1c control. All three found that males were more likely to
have poor HbA1c control (Juarez et al., 2014; Kamal et al., 2014; Lee et al., 2018). The fourth
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study (LeBlanc et al., 2015) reported that males who had higher baseline HbA1cs, used insulin,
and had a lengthier duration of DM were more likely to have poor control. In regard to duration
of disease, Juarez et al. (2014) found that those with DM for 10 years or more were more likely
to have HbA1c above the American Diabetes Association guidelines’ goal of less than 7%.
Considering that gender is not a quantitative variable, its relationship to HbA1c values was not
reviewed in this study.
Nelson (2002) reported that “disparities in healthcare exist even when insurance status,
income, age and severity of conditions are comparable” (p. 666). These disparities have a greater
impact on death rates from DM in racial and ethnic minorities than in whites (Nelson, 2002).
Race is commonly captured in EMRs and was evaluated in three of the reviewed studies. Juarez
et al. (2014) found that in a sample of patients enrolled in a large health plan in Hawaii, Native
Hawaiians were more likely to be above the American Diabetes Association’s goal for HbA1c
than other groups, such as whites, Japanese, and other Pacific Islanders. Lee et al. (2018) found
that the proportion of minority residents in a census tract was a better predictor (with 86%
accuracy) of locations with poor HbA1c control, with the portion of non-Hispanic black residents
having the highest specificity (91%). Additionally, Li et al. (2019) found that African-Americans
were more likely to have hypoglycemia (OR 1.8), while being Hispanic was negatively associated
with hypoglycemia (OR 0.7). Considering that race is not a quantitative variable, its relationship
to HbA1c values was not reviewed in this study.
Provider Characteristics
Provider characteristics are not usually found in EMRs. However, one of the studies
reviewed, LeBlanc et al. (2015), examined provider characteristics for relationships with HbA1c
control. Le Blanc et al. looked at provider demographics, duration of employment with the
practice group, type of primary care training (internal medicine versus family practice), degree
(medical doctor versus nurse practioner/physician assistant), number of patients on the
provider’s panel, and percentage of patients with DM on their panels. The researchers found
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that none of the provider characteristics were associated with poor HbA1c control. They went so
far as to suggest that focusing on individual providers’ characteristics may not be a good use of
resources. Considering that these provider characteristics are not a quantitative variable, their
relationship to HbA1c values was not studied in this study.
Socioeconomic Factors
Socioeconomic factors such as income, education, employment, community safety, social
supports, and, indirectly, insurance coverage are generally considered contributing factors in
health outcomes (County Health Rankings, 2019). However, many of these factors are not
captured in most EMRs. Only two of the studies reviewed utilized socioeconomic factors in their
research. Lee et al. (2018) used census-tract-level socioeconomic factors and demographics of
minority race/ethnicity, poverty, low education, and low median income as predictor variables
in mapping “hot spots” of poor glycemic control (an HbA1c of greater than 9%). They found that
these characteristics were less accurate than the proportion of minority residents in predicting
hot spots of poor HbA1c control. The researchers reported that the accuracy of these
socioeconomic factors ranged from 70% to 78%, which might be the reason some of the
demographic factors, which had an accuracy of 86%, were better predictors. Additionally, Li et
al. (2019) found that having Medicaid coverage was positively associated with hypoglycemia (OR
1.5). Since these factors are not quantitative variables or are not available in the HFDB, their
relationship to HbA1c values was not reviewed in this study.
Comorbidities
Comorbidities such as heart disease and cardiovascular risks are known to be associated
with worse health outcomes (Valderas et al., 2009) and are available in the EMR administrative
data. Three of the reviewed studies assessed the association of certain comorbidities and blood
sugar. Juarez et al. (2014) looked at this association using the Johns Hopkins Adjusted Clinical
Group methodology for the International Classification of Diseases, Ninth Revision, Clinical
Modification to determine which patients were considered to have high morbidity. In patients
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with comorbidities, the researchers found that high morbidity was significantly associated with
well-controlled HbA1c levels of less than or equal to 7%. Kamal et al. (2014) reviewed the
association of obesity, low-density lipoprotein cholesterol values (LDL), high-density lipoprotein
cholesterol values (HDL), smoking status, and depression with HbA1c control. They found that
patients with poorly controlled HbA1c had a higher prevalence of obesity (body mass index
[BMI] greater than 30), LDL levels greater than or equal to 100 mg/dl (36%) and HDL less than
or equal to 40 mg/dl (51%). Smoking status did not have an association with HbA1c control, but
higher prevalence of depression was present among those with poorly controlled HbA1c.
Additionally, Li et al. (2019) found that infection within 30 days (OR 2.5), diabetic neuropathy
(OR 1.6), alcohol consumption (OR 1.6), chronic heart failure (OR 1.3), dementia (OR 1.5), and
hypoglycemia in the previous 12 months (OR 2.4) were all positively associated with
hypoglycemia. These variables that are quantitative common laboratory values were reviewed in
this study.
Duration of Disease
The duration of time that a patient has had DM is not typically found in EMR
administrative data, as it is not typically a discrete field. Two of the reviewed studies assessed
the relationship of the duration of a patient’s having DM with the control of HbA1c. Juarez et al.
(2014) found that longer durations of DM were significantly associated with poor HbA1c control.
For those with poor control, 48% had DM for 10 or more years, as compared to 35% with HbA1c
of less than or equal to 7%. LeBlanc et al. (2015) used the length of time a patient was in a
diabetic registry as a substitute for the length of time the patient had DM. Their research found
that for those in the diabetes registry with poorly controlled HbA1c, the odds of poor control
increased by 3% for each year they were in the registry. Since the duration of DM is not directly
available in the HFDB, it was not a variable reviewed in this study.
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Medication
The type of medication a patient is using for glucose control is a data point that can be
found in most EMRs, assuming the patient has been prescribed a medication while in the care of
that health system. Two reviewed studies assessed the correlation between medication type and
HbA1c control. Le Blanc et al. (2015) showed that “users of insulin were more than twice as
likely to have poor control than nonusers” (p. 603). Conversely, Juarez et al. (2014) found that
insulin users made up more than half of those with HbA1c in control. Li et al. (2019) found that
use of non-long-acting insulin and no antibiotic use within 30 days were positively associated
with hypoglycemia (OR 2.2) in patients, whereas use of long-acting insulin within 90 days (OR
0.7) was negatively associated with hypoglycemia. Further, Juarez et al.’s (2014) study indicated
that of those who had HbA1c levels that were considered out of control, 44% were on a single
oral medication, 7% were on multiple oral medications, and 23% were on oral medication and
insulin together. In contrast, respective figures for those considered controlled were 35%, 3%,
and 7%.
Differences among these study populations and different dosing of medications may
account for the differences in these studies. In addition, any administrative data for a health
system’s EMR only indicates what medication(s) were prescribed in an outpatient environment.
No objective data exist on whether or not a patient administered the medication or administered
it correctly. As type of medication prescribed is not a quantitative variable, it was not reviewed
in this study.
Intensification
LeBlanc et al. (2015) looked at intensification of medication therapy. They defined
intensification as “the addition of a new antihyper-glycemic medication or an increase in dosage
of a current oral medication” (p. 598) within 90 days of an elevated HbA1c. The researchers did
not establish any correlation between provider characteristics and intensification once a
patient’s HbA1c was above goal. They did, however, find that older patients with a greater
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change in their HbA1c values were more likely to have their medication therapy intensified (OR
1.54). In addition, the researchers found that a greater change in HbA1c in patients with an
initial controlled HbA1c was most strongly associated with the probability of intensification (OR
1.54). Since intensification is not a quantitative variable, it was not reviewed in this study.
HbA1c/Glucose Levels
There are generally a variety of laboratory values available in an EMR. HbA1c is a
laboratory value that is frequently found for DM patients. LeBlanc et al. (2015) reviewed
baseline HbA1c levels in relation to poor control. They found that patients with a baseline HbA1c
of greater than or equal to 7% had twelve times higher odds of poor control (OR 12.4). In
addition, Li et al. (2019) found a negative association between hypoglycemia and serum calcium
(OR 0.5). Due to the fact that baseline HbA1c is not readily identifiable in the HFDB, this
variable was not considered in this study.
Healthcare Utilization
If a health system has its scheduling platform integrated with its EMR, healthcare
utilization data are available for study. These data can be difficult to interpret depending on how
the scheduling system is designed, thus making it potentially difficult to study utilization. Three
of the studies reviewed here were able to access utilization data in order to assess their
relationship to HbA1c control. Kamal et al. (2014) found that the average number of office visits
per patient were higher in those with poor HbA1c control (5.15) than among all DM patients in
the sample (4.85) and all patients in the primary care group (2.34). LeBlanc et al. (2015) found
that patients with at least one visit to an endocrinologist were twice as likely to have poor control
(OR 2.31), but those with at least one visit to a specialist other than an endocrinologist were
more likely to have HbA1c that was controlled (OR 1.13).
Lee et al. (2018) sought to identify areas of poor glycemic control in New York City for
unique patients in a citywide A1c registry using indirect measures instead of a population-based
A1c registry. The researchers found that healthcare utilization measures more accurately
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identified geographic areas of poor glycemic control than demographic and socioeconomic
factors. Lee et al.’s research indicates that rates of inpatient hospitalizations and emergency
department visits should be included as quantitative variables that may correlate to glycemic
control. Because utilization data are not a quantitative laboratory value, they were not reviewed
in this study.
EMR Systems/Predictive Data
This last theme group focused on EMR systems being used to support decision-making
and predictive modeling. Three of the reviewed studies addressing this theme found that
predictive models can be successful using EMR data (Li et al., 2019; Sahni et al., 2018; Zhao et
al., 2019). Li et al. (2019) found that multiple logistic regression (LR), classification and
regression trees (CART), and random forest models were successful in and had similar
performance in predicting hypoglycemia when using EMR laboratory values of glucose and
serum calcium (random forest mean AUC 90%, LR mean AUC 89%, CART mean AUC 88%).
Sahni et al. (2018) studied the ability of EMR data to be used to predict 1-year mortality
in patients emergently admitted to the hospital. The researchers reported that a random forest
model using EMR data points of age, blood urea nitrogen (BUN), platelet count hemoglobin,
and creatinine was successful (AUC 0.86) at predicting 1-year mortality of this group. Zhao et al.
(2019) reported that a random forest regression model including the EMR data of recent
estimated glomerular filtration rate (eGFR), age, BMI, gender, obesity, hypertension, and
diabetes successfully predicted future eGFR (mean coefficient of determination 0.95). Even
though these studies do not directly address the study question of this project, they do support
the concept that EMR data can be used to predict future laboratory values and patient outcomes,
which is of value to this study.
In the fourth reviewed study addressing this theme, Adaji et al. (2008) performed a
systematic review of 25 articles related to DM and medical records systems. These researchers
found that EMR systems have been successfully used to support clinicians with timely access to
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data, as well as with reminders for evidence-based care, both of which improve the process
measures of DM care. However, Adaji et al. found that systems designed to remind clinicians of
evidence-based care did not improve patients’ laboratory values of HbA1c.
These studies do not show any associations between quantitative laboratory data and
DM. However, that is not the value these studies bring to the current project. Their value here
lies in the fact that they indicate EMR administrative data can be and has been used to
successfully predict patient laboratory values using a variety of statistical models.
Literature Synthesis
As evidenced by numerous studies on variables that correlate to blood glucose and
HbA1c, a limited set of quantitative and qualitative variables that impact blood glucose values
have been frequently studied. However, very few studies have narrowly focused on the
correlation of quantitative administrative data found in EMRs to HbA1c values, and even fewer
on the predictive ability of EMR administrative data. As healthcare evolves, health systems and
providers are in need of this research, as their reimbursements are becoming increasingly tied to
the attainment of outcome measures, such as those of HEDIS. Additionally, utilizing this
research will help health systems attain their goal of providing better healthcare. In the reviewed
studies that addressed this question, the study populations tended to be so specific that the
studies’ generalizability to the general population or other populations is questionable.
Therefore, more research on the subject is needed. The current project was intended to help fill
that gap.
Thus far, existing research has indicated that potentially multiple variables have a
statistically significant impact on blood glucose or HbA1c levels. Those potential variables are
patient age, duration of disease, medication type, life style factors, BMI, comorbidities,
race/ethnicity, LDL, HDL, HbA1c levels, serum calcium, healthcare utilization, the diagnosis of
depression, and infection within the past 30 days, not all of which are quantitative laboratory
values. However, these variables may very well be specific to the populations that were studied,
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and some of the impact results are contradictory. Therefore, clinicians need clearer guidance on
which data points found in their EMR’s administrative data are potential predictors of which
patients are more likely to have HbA1c levels that are out of control.
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CHAPTER 3: THEORETICAL MODEL AND METHODOLOGY
Theoretical Model
DM is a disease in which the actions of the person with the disease have a great impact
on the outcomes and trajectory of the disease’s effects. Since the course of this disease is highly
contingent on the patient, healthcare providers have an obligation to help patients achieve the
best outcome possible. Therefore, the theory of planned change (TPC) was chosen as the
theoretical framework for this study.
Kurt Lewin, a social psychologist of the early 20th century who is considered the father of
social psychology, developed the TPC (Lewin, 1997; Shirey, 2013). The TPC consists of three
stages or phases: unfreezing, moving or transition, and refreezing (Shirey, 2013). Within these
three phases, there are driving forces and restraining forces (Shirey, 2013). Driving forces help
move patients toward the desired change or goal, while restraining forces hinder patients from
moving toward the change or goal (Shirey, 2013).
In the phase of unfreezing, healthcare providers can assist patients in moving toward
change (moving phase) by helping them recognize the potential negative outcome from the
trajectory of their disease. Identifying the quantitative variables that indicate when patients are
on a negative trajectory with their disease process gives healthcare providers additional driving
force to share with patients: a quantifiable forecast of their HbA1c.
Methodology
Study Population
This retrospective qualitative study used de-identified patient data from the HFDB. The
HFDB consists of over 158,300,000 patients from across the nation. Approximately 435,476
unique patients with DM with at least one HbA1c lab result existed in the HFDB between July 1,
2016 and July 1, 2017. Of those, 21,108 had an HbA1c result greater than 8% after the date of
diagnosis of DM. For this study, only the first HbA1c value after the diagnosis of DM and the
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independent variables closest in time to that HbA1c value (regardless of directionality) were
used.
Power analysis performed using G*Power (Heinrich Heine Universität Düsseldorf, 2020)
indicated that this sample of 21,108 should have sufficient (80%) statistical power to detect very
small effect sizes of Cohen’s f2 = .0004 using a threshold of p = .05. The racial and gender makeup of this population was varied due to the large sample size and geographic spread of the
facilities that report to the database; however, it does not match the racial make-up of the
population of the United States. This decreases the generic applicability of this study. Honing
the study to specific populations would be a step for further research.
Sampling Procedure
The HFDB is a database comprised of patient records from over 600 participating
hospitals and clinics that have a Cerner EMR. The longitudinal, relational data from over 106
million unique patients are de-identified and available at the patient level. Data in HFDB are
extracted directly from the EMR from hospitals with which Cerner has a data use agreement.
Encounters may include pharmacy, clinical and microbiology laboratory, admission, and billing
information from affiliated patient care locations. All admissions, medication orders and
dispensing, laboratory orders, and specimens are date and time stamped, providing a temporal
relationship between treatment patterns and clinical information. Cerner Corporation has
established operating policies compliant with the Health Insurance Portability and
Accountability Act (HIPAA) to establish de-identification for HealthFacts (University of New
Mexico Health Sciences Center, n.d.-b).
Prior to the requesting of the data for this study, Institutional Review Board permission
was obtained from the University of New Mexico Health Sciences Center (see Appendix). The
sample for this study included all unique adult patients within the database identified with the
diagnosis of DM. The time period for this study was July 1, 2016 and July 1, 2017. With a final
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sample size of 21,108 patients, the power of this study is that it is able to detect very small effect
size correlations in the data.
Study Design
The study design was a retrospective quantitative analysis with multiple linear regression
to assess the presence of a relationship between the predictor variables (independent variables)
and the outcome variables of HbA1c greater than 8%. The regression analysis identified the
variables with statistically significant correlations. In addition to the correlations, the effect size
of the correlation was also identified for each of the variables using Cohen’s f-squared.
Regression beta coefficients were also identified in the analysis.
Ethical Issues
This study did not present any specific ethical concerns. Through the use of the HFDB
and an honest broker, participant confidentiality was guaranteed since the database contained
only de-identified patient data. Data points contained a patient identifier that was not traceable
back to the patient for the purpose of identifying which data came from which patient.
Data Protection Plan
The data protection plan for this study was governed by the University of New Mexico
Health Science Center’s HFDB Data Use Agreement. All HFDB data was only used by the
recipient and approved study team. Data were not used to re-identify any person, nor were they
redistributed by any method. Data were kept on a secured drive behind the firewall at the
University of New Mexico Health Sciences Center and accessed only by the approved study
team.
Statistical Analysis
All data requested from the HFDB met inclusion criteria. A significant number of patient
records did not include an HbA1c value greater than 8% after the date of diagnoses with DM.
These patient records were not included in the final analysis. Due to the large data size,
statistical analysis and computer power had to be obtained from the University of New Mexico’s
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Clinical and Translational Science Center.
Descriptive statistics were used to summarize basic demographic information within the
sample from the categorical variables. Multiple linear regression analysis was used on the
quantitative laboratory values to determine correlations with the HbA1c values. The adjusted Rsquared was converted to a Cohen's f-squared using the formula described by Cohen (1988)
(f2 = R2 / [1 - R2]) since G*Power, which was used for the power analysis, relies on Cohen’s fsquared (Faul et al., 2009).
The R-squared was adjusted for age, race/ethnicity, marital status, and urban/rural
status. Therefore, any correlations found are for the entire model, including the adjustment
variables, rather than the independent variable alone.
Budget
The budget for this analysis was $3,000 for 40 hours of biostatistician time to run the
statistical analysis at the University of New Mexico’s Clinical and Translational Science Center.
This cost was paid for by the student-investigator. No other costs were incurred.
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CHAPTER 4: RESULTS AND DISCUSSION
Of the 21,108 patients in the final sample, 10,736 (51%) were male and 10,371 (49%)
were female. One (<1%) patient record missing gender was kept in the data. Median age of the
patients represented in the data was 60 years. The majority were white (n = 14,481, 69%), male
(n = 10,736, 51%), single (n = 9,962, 47%), and living in an urban environment (n = 15,375,
73%). Table 3 presents the demographic characteristics of the participants.
Table 3
Demographic Characteristics of Participants (n = 21,108)
Demographic Characteristic
Age
Race/Ethnicity
White
Black
Asian
Native
Hispanic
Gender
Male
Female
Marital Status
Single
Widowed
Divorced/separated
Other
Urban
Rural

Median (IQR) or n (%)
60 (51, 69)
14,481 (68.6%)
3,965 (18.8%)
2,145 (10.2%)
393 (1.9%)
124 (0.6%)
10,736 (50.9%)
10,371 (49.1%)
9,962 (47.2%)
5,796 (27.5%)
2,059 (9.8%)
2,592 (12.3%)
15,374 (72.8%)
5,734 (27.2%)

The multiple linear regression analysis is shown in Table 4. The independent variables
absolute lymphocyte count (ALC), absolute monocyte count (AMC), and absolute neutrophil
count (ANC) are represented on Table 4 but did not have multiple linear regression run due to
the small sample size.
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Table 4
Association of HbA1c Levels to Other Common Laboratory Values
EMR Laboratory
Value

n

Correlation
Coefficient (95% C.I.)

p-Value

Adjusted
R2 a

Adjusted
Cohen's f2 a

15,937

-0.03 (-0.03 to -0.02)

<0.0001

0.04

0.04

ALC

8

NA

NA

NA

NA

ALP

17,929

3.53 (3.26 to 3.80)

<0.0001

0.05

0.05

ALT

16,880

-0.39 (-0.51 to -0.27)

<0.0001

0.05

0.05

AMC

456

NA

NA

NA

NA

ANC

55

NA

NA

NA

NA

Anion Gap

15,092

0.14 (0.10 to 0.18)

<0.0001

0.04

0.04

AST

16,319

-0.28 (-0.38 to -0.18)

<0.0001

0.01

0.01

Bilirubin

15,520

0.01 (0.00 to 0.01)

<0.0001

0.01

0.01

BUN

18,994

0.14 (0.07 to 0.20)

<0.0001

0.12

0.14

Calcium

14,990

0.00 (-0.01 to 0.00)

0.2176

0

0

Chloride

18,255

-0.49 (-0.53 to -0.45)

<0.0001

0.05

0.05

Carbon Dioxide

14,989

-0.22 (-0.25 to -0.19)

<0.0001

0.04

0.04

Creatinine

16,140

0.00 (0.00 to 0.00)

0.2769

0.11

0.12

Glucose

16,460

21.66 (20.83 to 22.49)

<0.0001

0.17

0.2

Hematocrit

16,407

0.05 (0.00 to 0.09)

0.0311

0.05

0.05

HDL

15,657

-0.12 (-0.25 to 0.00)

0.049

0.02

0.02

Hemoglobin

17,642

0.06 (0.05 to 0.08)

<0.0001

0.09

0.1

LDL

6,613

2.37 (1.83 to 2.91)

<0.0001

0.05

0.05

MCV

17,241

-0.20 (-0.25 to -0.15)

<0.0001

0.07

0.08

MPV

13,514

0.02 (0.01 to 0.03)

0.0029

0.01

0.01

Platelets

17,281

0.60 (-0.05 to 1.24)

0.0687

0.03

0.03

Potassium

18,266

0.00 (0.00 to 0.00)

0.8895

0.02

0.02

Red Blood Cells

14,238

0.02 (0.01 to 0.02)

<0.0001

0.08

0.09

Total Protein

16,954

0.00 (0.00 to 0.01)

0.4124

0.04

0.04

Triglycerides

13,641

4.34 (3.42 to 5.26)

<0.0001

0.04

0.04

VLDL

4,425

0.72 (0.40 to 1.04)

<0.0001

0.03

0.03

White Blood Cell

14,274

0.06 (0.03 to 0.09)

<0.0001

0.02

0.02

Albumin

Note. Acronyms can be found in the List of Acronyms on page 11.
a

Adjusted for age, race/ethnicity, marital status, and urban/rural status.
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A statistically significant association existed between HbA1c and 21 of the 29
independent variables, with p-values ranging from 0.049 to <0.0001. The laboratory values of
calcium, creatinine, platelets, potassium, and total protein did not have a significant association
to HbA1c. Of the remaining statistically significant associations, all were found to have small
effect sizes (Cohen's f2 between 0.02 and 0.14), except for glucose, which had a medium effect
size (Cohen's f2 = 0.2). The independent variables were found to have mostly small correlation
coefficients. Glucose, triglycerides, alkaline phosphatase (ALP), and LDL were found to have the
largest correlation coefficients, respectively 21.66, 4.34, 3.53, and 2.37. The other statistically
significant independent variables had smaller correlation coefficients ranging from -0.51 to 0.72.
Interpretation of Findings
Due to large size of the sample, statistical analysis had the ability to find some of the
smallest correlations that existed in the data set between the common laboratory values and
HbA1c values, as revealed in the large number of variables found to have a statistically
significant association to HbA1c with a small effect size. While statistically significant, these
laboratory values only explain a small portion of the variability in the HbA1c. Due to the
statistical power of this analysis, the effect size and correlation coefficient were considered in
addition to statistical significance. Based on the analysis of the statistical data, four variables are
worthy of note.
First, a medium effect size (Cohen’s f2 = 0.2) and what appears to be a large correlation
coefficient (21.66; 95% CI [20.83, 22.49]) existed in addition to the statistical significance
between glucose values and HbA1c (p <0.0001). It is logical that glucose values would be
associated with HbA1c values, as an HbA1c value is a marker of average glucose values over the
previous three months (Nitin, 2010). The correlation coefficient of 21.66 indicates that for every
one unit increase in HbA1c, glucose rises by 21.66 units. This sounds like a significant number;
however, on its own, a 21.66 unit rise in glucose would not necessarily be a large enough
fluctuation to alert a clinician.
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Three other variables of note are ALP, LDL, and triglycerides. Each showed a statically
significant association with HbA1c values (p < 0.0001). The correlation coefficient for these
variables is larger than those of the other statistically significant variables. The correlation
coefficient for ALP indicates that for every single unit of increase in HbA1c, an associated
increase in ALP of 3.53 units (95% CI [3.26, 3.80]) exists. As with the glucose variable, this
number on its own may appear significant, but it is unlikely that a 3.53 unit rise in ALP would be
enough for a clinician to be alerted. In addition, the effect size for this variable was small,
indicating that this variable alone in the model accounts for only a very small portion of the
variability in HbA1c.
The relationship of LDL and triglycerides to HbA1c is similar to that of ALP in that both
have a small effect size. This indicates that each variable accounts for only a very small portion
of the variability in HbA1c and the correlation coefficients may appear to be large numbers (2.37
and 4.24 respectively), as compared to the other variables in the analysis. However, on their
own, a 2.37 rise in LDL and 4.24 rise in triglycerides are most likely not enough to alert a
clinician.
An issue that was not considered in this study but which may impact the effect size of
these statistically significant associations is chronologic directionality of the independent
variables in relation to the dependent variables. The sequencing of laboratory values may have
influenced the association of the variables. If the independent variable occurs prior to or after
the time of the dependent variable, the statistical significance of the association, as well as the
effect size, may be impacted.
Discussion
This study used qualitative methods and sought to understand the association between
uncontrolled HbA1c and commonly available EMR administrative data. To date, it is the only
study to consider common EMR laboratory values (administrative data) in the HFDB in relation
to HbA1c greater than 8%, and as such, contributes to the limited body of knowledge currently
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available in the literature. The results of this study do not support findings from prior studies, as
the study question and analysis were significantly different than those in the studies reviewed.
The aim of this study was to identify which quantitative data elements in the HFDB correlate to
poorly controlled HbA1c levels in adult patients with DM that could be used in the future to
create a mathematical model to predict which patients may have poorly controlled HbA1c levels.
This study was the first step in a multistep process to identify the predictor variables and create
such a mathematical model.
The key finding from this study was that the majority of the common quantitative
laboratory values (as adjusted) in the HFDB had a significant statistical association with HbA1c
of greater than 8%; however, the effect sizes of those associations were small and, therefore,
account for very little of the HbA1c variability. The only exception was the glucose variable. The
glucose association to HbA1c was statistically significant and had a medium effect size. The
association between glucose and HbA1c was expected, as HbA1c is a measure of average glucose
over the preceding three months, and glucose has been previously found to have a linear
relationship to HbA1c (Rohlfing et al., 2002). Therefore, this study further contributed to the
body of knowledge the fact that no single quantitative laboratory value in the HFDB was
strongly associated with poorly controlled HbA1c during the study period.
Implications for Practice
This study contributes to the body of knowledge the fact that there is not a single
quantitative laboratory value in the HFDB that is strongly associated with poorly controlled
HbA1c for the study time period. Glucose, with a medium effect size, has been the long-standing
canary in the coal mine for patients with DM. No new single variable can be reviewed to clue in
the clinician to a potential future HbA1c value of greater than 8%. Therefore, there are no
immediate implications for practice change that can be deduced from this study, and clinicians
need to continue to follow existing evidence-based practices for the care of the adult diabetic
patients.
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Limitations and Strengths of the Study
Limitations
In this study, the large sample size is not only a strength but also a limitation. The ability
of this analysis to detect very small effect size, statistically significant correlations in the data is a
potential limitation, in that a very small effect size means that the independent variable may or,
most likely, may not contribute much to variation in the dependent variable. Also due to the
large sample size, additional computing power beyond the average home or office computer
system was needed for the statistical analysis of such a large dataset. Even with the large data
set, this study is not generalizable to all populations due to the demographic makeup of the
sample.
In addition, chronologic directionality was not considered in this study. When the
independent variable occurs prior to the dependent variable, it is more likely that the
independent variable may have an association with the dependent variable that may be used for
predictive models. However, if the independent variable occurs after the dependent variable, the
independent variable would not be able to be used for predictive models. Setting the
directionality of the variables sequencing would be important for refining this study.
Additionally, other factors that were not studied or adjusted for might have impacted the
associations between the independent variables. Factors such as the life span of red blood cells
have been shown to impact the percentage of HbA1c (Cohen et al., 2008). Therefore, identifying
the hematological factors that impact HbA1c could be a potentially important step in refining a
model to predict HbA1c control.
Strengths
The study had several strengths. First, with the sample coming from the HFDB through
an honest broker, the risk of privacy or HIPAA compliance issues was minimized since all data
had been de-identified prior to receipt. Second, with the large sample size, the statistical power
detected very small effect size correlations in the data. In addition, investigator bias was limited

35

since there was no qualitative data interpretation and no interactions between the investigator
and participants. Also, notably, the study would be relatively easy to replicate due to the ease
and speed of accessing the HFDB.
Suggestions for Further Research
Given that HbA1c control is tied so closely with patient health and health system
reimbursement, it is important for further studies building on this study to determine if a
combination of independent variables exists that might lead to a predictive model of which adult
DM patients are at risk for poorly controlled HbA1c. The independent variables identified in this
study as statistically significant with a small effect size may very well lead to a larger effect size
when combined with other independent variables in a multiple regression model. In addition,
chronologic directionality of the variables should also be considered in future research.
Other independent variables commonly found in EMRs such as age, gender, and race
could also be included in future studies, as conflict currently exists in the literature as to which
variables contribute to HbA1c levels. In addition, honing research to specific racial/ethnic
populations would improve the generalizability to those populations and may improve the
predictive ability and fidelity of any model created, as differences in laboratory values exist for
different racial, ethnic, and gender groups (Bergenstal et al., 2018; Beutler & West, 2005; Lim et
al., 2015; Sellami et al, 2017).
Additionally, other methods of statistical analysis should be considered in further
research. Previous researchers reported success in using multiple logistic regression, CART, and
random forest models. Using one of these other models for analysis could improve the
identification of variable associations.
Concluding Remarks
The potential to create mathematical models that predict which patients are at risk for
complications or diseases is no longer a figment of science fiction. However, we are still in the
infancy of being able to create such mathematical models with precision and fidelity. As DM is
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one of the most costly chronic diseases with some of the lowest quality of life rates in the United
States, being able to reasonably predict which patients will have uncontrolled HbA1c is a worthy
research endeavor and should be continued beyond this study.
This study has advanced the understanding of the association between poorly controlled
HbA1c and some of the common quantitative laboratory values found in EMRs around the
nation. However, this is only a starting point in a multistep process required to achieve the goal
of creating a predictive model for patients at risk for uncontrolled HbA1c. Further studies are
needed to determine the combination of variables that will be successful in creating a predictive
model. With such a model, clinicians will be able to intervene earlier with patients at risk for
poorly controlled HbA1c, thus increasing the ability of DM patients to adjust their actions and
change the outcomes and trajectory of their disease.
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